Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03722420|
Recruitment Status : Recruiting
First Posted : October 29, 2018
Last Update Posted : February 12, 2020
This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD).
This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).
|Condition or disease||Intervention/treatment||Phase|
|Chronic Myeloid Leukemia, Chronic Phase||Drug: Radotinib Drug: Imatinib||Phase 3|
Patients randomized to the radotinib arms will receive 300 mg of radotinib BID at approximately 12-hour intervals. Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
The primary efficacy endpoint is the rate of Major Molecular Response(MMR) at 12 months (1 month = 4 weeks = 28 days), defined as BCR ABL1/ABL% ≤ 0.1% by international scale. The Molecular Response(MR) rate will be measured every 3 months by Real-time Quantitative(RQ)-Polymerase Chain Reaction(PCR) in a central laboratory. All patients will be treated and/or followed for 12 months (48 weeks) after randomization.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||238 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Parallel, 2 arms|
|Masking:||None (Open Label)|
|Official Title:||A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase|
|Actual Study Start Date :||December 28, 2018|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||December 31, 2023|
Experimental: Radotinib 300mg
Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
Other Name: Supect
Active Comparator: Imatinib 400mg
Oral administration of Imatinib 400mg QD (400mg/day) for 12months
Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
Other Name: Glivec
- The MMR rate [ Time Frame: at 12 months after radotinib or imatinib treatment ]The MMR rate at 12 months after radotinib or imatinib treatment in patients with newly diagnosed CML-CP.
- MMR rate [ Time Frame: by 3, 6, 9, and 12 months of treatment. ]To compare MMR rate for the best response in patients within specific periods.
- Complete Cytogenetic Response(CCyR) rate [ Time Frame: by 3, 6, 9, and 12 months of treatment. ]To compare CCyR rate for the best response in patients within specific periods.
- The MR 4.0 and MR 4.5 rates [ Time Frame: by 3, 6, 9, and 12 months of treatment, and late ]To compare the MR4.0 and MR4.5 rates for the best response in patients within specific periods.
- Disease progression (AP/BC) rate [ Time Frame: at 3, 6, and 12 months ]To compare disease progression for the best response in patients within specific periods.
- Failure rate according to European Leukemia Net (ELN) guideline 2013 (ELN 2013*) [ Time Frame: at 3, 6, and 12 months ]To compare failure rate for the best response in patients within specific periods.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03722420
|Contact: Jeong H Kimemail@example.com|
|Contact: Bo Hwangbofirstname.lastname@example.org|
|Peking University People's Hospital(北京大学人民医院)||Recruiting|
|Beijing, China, 100044|
|Contact: Jiang Qian|
|Principal Investigator:||Jiang Qian||Peking University People's Hospital(北京大学人民医院)|